Related Experiment Video

Updated: Jun 2, 2026

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Onset of heart failure determines the hepatic cell death pattern

Kerstin Herzer1, Guntje Kneiseler, Lars Peter Bechmann

  • 1Department for Gastroenterology and Hepatology, University Hospital Essen, Hufelandstr, Germany.

Annals of Hepatology
|April 20, 2011
PubMed

Insights

Acute heart failure (AHF) causes more liver cell death than chronic heart failure (CHF). Higher M30 levels in AHF indicate worse prognosis, suggesting M30 as a survival marker for liver injury.

Area of Science:

  • Hepatology
  • Cardiology
  • Biomarkers

Background:

  • Heart failure (HF) can impact liver function, but mechanisms of liver damage are unclear.
  • Hepatic cytokeratin-18 (CK18) epitopes M65 and M30 indicate overall and apoptotic cell death, respectively.

Purpose of the Study:

  • To determine the predominant hepatic cell death pattern in acute versus chronic heart failure.
  • To assess if CK18 assays predict disease progression in heart failure patients.

Main Methods:

  • Prospective study of 21 acute HF (AHF) and 18 chronic HF (CHF) patients.
  • Serum levels of CK18 M65 and M30 were measured.

Main Results:

  • M65 and M30 levels were significantly higher in AHF compared to CHF.
  • The M30/M65 ratio was significantly higher in CHF, indicating greater apoptotic cell death.
  • Elevated M30 levels in AHF correlated with a worse prognosis.

Conclusions:

  • The CK18 M30/M65 ratio may differentiate AHF from CHF-induced liver disease.
  • M30 may serve as a prognostic marker for survival in AHF-induced liver injury.
Abstract

More Related Videos

Cell Type-specific Gene Expression Profiling in the Mouse Liver10:06

Cell Type-specific Gene Expression Profiling in the Mouse Liver

Published on: September 17, 2019

Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice10:04

Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice

Published on: December 2, 2022

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...